As of 2024-12-15, the EV/EBITDA ratio of Blueprint Medicines Corp (BPMC) is -23.76. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BPMC's latest enterprise value is 6,217.57 mil USD. BPMC's TTM EBITDA according to its financial statements is -261.71 mil USD. Dividing these 2 quantities gives us the above BPMC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.3x - 14.6x | 12.8x |
| Forward P/E multiples | 13.9x - 16.1x | 15.2x |
| Fair Price | (62.02) - (64.99) | (62.45) |
| Upside | -166.6% - -169.7% | -167.0% |
| Date | EV/EBITDA |
| 2024-12-13 | -23.76 |
| 2024-12-12 | -23.61 |
| 2024-12-11 | -24.07 |
| 2024-12-10 | -24.29 |
| 2024-12-09 | -24.09 |
| 2024-12-06 | -24.43 |
| 2024-12-05 | -24.22 |
| 2024-12-04 | -24.57 |
| 2024-12-03 | -24.57 |
| 2024-12-02 | -24.83 |
| 2024-11-29 | -24.53 |
| 2024-11-27 | -24.22 |
| 2024-11-26 | -24.11 |
| 2024-11-25 | -23.92 |
| 2024-11-22 | -23.99 |
| 2024-11-21 | -24.59 |
| 2024-11-20 | -24.15 |
| 2024-11-19 | -24.10 |
| 2024-11-18 | -23.03 |
| 2024-11-15 | -22.67 |
| 2024-11-14 | -24.35 |
| 2024-11-13 | -24.65 |
| 2024-11-12 | -24.59 |
| 2024-11-11 | -25.38 |
| 2024-11-08 | -25.61 |
| 2024-11-07 | -25.75 |
| 2024-11-06 | -25.32 |
| 2024-11-05 | -24.82 |
| 2024-11-04 | -23.44 |
| 2024-11-01 | -23.15 |
| 2024-10-31 | -22.38 |
| 2024-10-30 | -22.80 |
| 2024-10-29 | -21.38 |
| 2024-10-28 | -21.23 |
| 2024-10-25 | -21.16 |
| 2024-10-24 | -21.31 |
| 2024-10-23 | -21.62 |
| 2024-10-22 | -22.13 |
| 2024-10-21 | -21.92 |
| 2024-10-18 | -22.01 |
| 2024-10-17 | -22.01 |
| 2024-10-16 | -22.82 |
| 2024-10-15 | -22.78 |
| 2024-10-14 | -22.66 |
| 2024-10-11 | -22.69 |
| 2024-10-10 | -22.25 |
| 2024-10-09 | -22.40 |
| 2024-10-08 | -22.37 |
| 2024-10-07 | -22.82 |
| 2024-10-04 | -22.65 |